
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Recipient : Quantum Genomics
Deal Size : Undisclosed
Deal Type : Collaboration
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran
Details : Under the terms of the agreement, Faran will receive the exclusive rights to market Firibastat for the treatment of difficult-to-treat / resistant hypertension in Greece.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $12.1 million
December 15, 2020
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Recipient : Quantum Genomics
Deal Size : Undisclosed
Deal Type : Collaboration
